A potent TRPV1 antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

BCTC

Item No. 10006309

Technical Information
Formal Name
4-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide
CAS Number
393514-24-4
Molecular Formula
C20H25ClN4O
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 20 mg/mlDMF:PBS (pH 7.2)(1:3): 0.25 mg/mlDMSO: 12.5 mg/mlEthanol: 10 mg/ml
λmax
247 nm
SMILES
ClC1=CC=CN=C1N2CCN(C(NC3=CC=C(C(C)(C)C)C=C3)=O)CC2
InChi Code
InChI=1S/C20H25ClN4O/c1-20(2,3)15-6-8-16(9-7-15)23-19(26)25-13-11-24(12-14-25)18-17(21)5-4-10-22-18/h4-10H,11-14H2,1-3H3,(H,23,26)
InChi Key
ROGUAPYLUCHQGK-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    BCTC is a potent TRPV1 antagonist that inhibits capsaicin-induced and acid-induced activation of rat TRPV1 with IC50 values of 35 and 6 nM, respectively.1,2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Valenzano, K.J., Grant, E.R., Wu, G., et alN-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1 (2H)-carbox-amide (BCTC), a novel orally effective vanilloid receptor 1 antagonist with analgesic properties: I. In vitro characterization and pharmacokinetic properties. J. Pharmacol. Exp. Ther. 306(1), 377-386 (2003).

    2. Gavva, N.R., Tamir, R., Klionsky, L., et alProton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol. Pharmacol. 68(6), 1524-1533 (2005).